<DOC>
	<DOCNO>NCT01545882</DOCNO>
	<brief_summary>This study offer patient hormone resistant prostate cancer ( HRPC ) . This mean prostate cancer longer respond standard hormonal therapy . The purpose study determine whether Degarelix able stop PSA rise patient hormone resistant prostate cancer .</brief_summary>
	<brief_title>A Phase II Study Degarelix Management Non-Metastatic Hormone-Refractory Prostate Cancer</brief_title>
	<detailed_description>This phase II study GnRH antagonist drug , Degarelix , use hormone resistant prostate cancer patient biochemical PSA progression despite use total androgen blockade therapy . Patients receive least six monthly injection Degarelix unless patient show radiographic symptomatic disease progression , intolerable toxicity decide withdraw study . Patients evaluate measure efficacy , toxicity disease progression treatment afterwards radiologically confirm metastatic disease progression patient remove study . Overall objective : The efficacy Degarelix treatment HRPC evaluate</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Androgens</mesh_term>
	<criteria>Prior trial total androgen blockade Confirmed biochemical PSA progression agonist therapy , define ≥ 50 % increase PSA 2 measurement , take least 1 week apart . In patient currently total androgen blockade ( LHRH agonist plus nonsteroidal antiandrogen ) must trial withdrawal androgen receptor antagonists ensure PSA response ( 6 week bicalutamide 4 week flutamide nilutamide ) . Radiologically confirm nonmetastatic disease within 90 day registration base negative chest radiograph , CT Scan Abdomen/Pelvis Bone scan ECOG ≤ 2 Age ≥ 18 year Serum testosterone ≤ 50 mg/dl PSA ≥ 2.0 ng/ml White blood cell count ≥ 3000/mm3 Platelets ≥ 100,000/mm3 Serum creatinine ≤ 1.5 x upper limit normal Bilirubin ≤ 1.5 x upper limit normal Alanine transaminase ≤ 1.25 x upper limit normal Estimated life expectancy least 12 month Able willing sign inform consent Prior treatment chemotherapy , radiopharmaceutical , estrogen , PCSPES , ketoconazole second line hormonal therapy ( nonsteroidal antiandrogens Androcur ) Known allergy GnRH agonists antagonists Previous treatment Degarelix Major surgery within 4 week registration Grade ≥ 3 peripheral neuropathy Severe , active comorbidity unstable angina , congestive heart failure myocardial infarction within last 6 month congenital long QT syndrome Acute deep vein thrombosis pulmonary embolism Taking antiarrhythmia medication Second malignancy nonmelanoma skin cancer unless disease free ≥ 5 year . Prior orchiectomy prostate cancer PSA &gt; 100 ng/mL</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>prostate</keyword>
	<keyword>hormone-resistant</keyword>
	<keyword>degarelix</keyword>
	<keyword>firmagon</keyword>
	<keyword>anti-androgens</keyword>
	<keyword>total androgen blockade</keyword>
	<keyword>injection</keyword>
</DOC>